EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Aspects biologiques, précliniques et cliniques de l’association de radiothérapie et d’inhibiteur de CDK 4/6

A Beddok, B Porte, P Cottu, A Fourquet, Y Kirova

Cancer/Radiothérapie · 2023

DOI: 10.1016/j.canrad.2022.11.003 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer/Radiothérapie, 2023. Verfasst von A Beddok und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institut Curie, PSL Research University, University Paris Saclay, Inserm LITO, 91898 Orsay, France; Institut Curie, PSL Research University, Radiatio…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Breast Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 65 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Several clinical studies have shown that CDK4/6 inhibitors (CDK4/6i) improve survival in patients with metastatic or locally advanced HR-positive, HER-2-negative breast cancer (BC). The aim of this review was to synthesize the biological, preclinical and clinical aspects of the treatment of BC with CDK4/6i, with a focus on the combination of CDK4/6i and radiotherapy. The DNA damage induced after exposure of cells to ionizing radiation activates control pathways that inhibit cell progression in the G1 and G2 phases and induce a transient delay in progression in the S phase. These checkpoints are in particular mediated by cyclin-dependent kinases (CDK) 4/6 activated by cyclin D1. Several preclinical studies have shown that CDK4/6i could be used as radiosensitizers in non-small cell lung cancer, medulloblastoma, brainstem glioma and breast cancer. CDK4/6 inhibition also protected against radiation-induced intestinal toxicities by inducing redistribution of quiescent intestinal progenitor cells, making them less radiosensitive. Clinical data on the combination of CDK inhibitors and radiotherapy for both locoregional and metastatic irradiation are based on retrospective data. Nevertheless, the most optimal therapeutic sequence would be radiotherapy followed by palbociclib. Pending prospective clinical trials, the concomitant combination of the two treatments should be done under close supervision.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsBreast NeoplasmsHumansFemaleProspective StudiesRetrospective StudiesCyclin-Dependent Kinase 6Protein Kinase InhibitorsCyclin-Dependent Kinase 4

Stichwörter der Autor:innen

CDK inhibitorInhibiteur de CDKMultimodal therapyPalbociclibToleranceToléranceTraitement multimodal

Substanzen

Cyclin-Dependent Kinase 6Protein Kinase InhibitorsCDK4 protein, humanCyclin-Dependent Kinase 4

Autor:innen und Institutionen

  • Institut Curie, PSL Research University, University Paris Saclay, Inserm LITO, 91898 Orsay, France; Institut Curie, PSL Research University, Radiation Oncology Department, Proton Therapy Centre, Centre Universitaire, 91…
  • Service d'oncologie médicale, GHU hôpital européen Georges-Pompidou, Paris, France.
  • Département d'oncologie médicale, Institut Curie, Paris, France.
  • Institut Curie, PSL Research University, Radiation Oncology Department, Paris, France.

Zitieren

APA

Beddok, A., Porte, B., Cottu, P., Fourquet, A., & Kirova, Y. (2023). Aspects biologiques, précliniques et cliniques de l’association de radiothérapie et d’inhibiteur de CDK 4/6. Cancer/Radiothérapie. https://doi.org/10.1016/j.canrad.2022.11.003

Vancouver

Beddok A, Porte B, Cottu P, Fourquet A, Kirova Y. Aspects biologiques, précliniques et cliniques de l’association de radiothérapie et d’inhibiteur de CDK 4/6. Cancer/Radiothérapie. 2023. doi:10.1016/j.canrad.2022.11.003

BibTeX
@article{Beddok2023,
  author = {Beddok, A and Porte, B and Cottu, P and Fourquet, A and Kirova, Y},
  title = {Aspects biologiques, précliniques et cliniques de l’association de radiothérapie et d’inhibiteur de CDK 4/6},
  journal = {Cancer/Radiothérapie},
  year = {2023},
  doi = {10.1016/j.canrad.2022.11.003}
}
Kostenlos starten →